

MARILLION PHARMACEUTICALS

Marillion Pharmaceuticals is a newly-created pharmaceutical company focused on the discovery of novel drugs to treat cancers.

Formed around technology exclusively licensed from the University of Pennsylvania, Marillion's powerful scientific approach enables cancer fighting drugs to enter and be trapped within tumor cells by exploiting a specific glucose transport system found in most malignant tumors. The chemotherapeutic agent is then able to selectively destroy the tumor while preserving healthy tissue and minimizing side effects.

Initially, Marillion's drug discovery efforts will focus on breast cancer, but its products are expected to be widely applicable to other debilitating and life threatening cancers. About 10 million people worldwide develop cancer annually—and 6 million die from the disease.

Based on discoveries in the laboratories of Dr. Gang Zheng and Dr. Jerry Glickson at the University of Pennsylvania, the company's proprietary technology links cancer-fighting chemotherapy to a form of glucose called 2-deoxyglucose, or "2DG," used by most tumor cells as their primary source of energy. Attaching a chemotherapeutic agent to the 2DG molecule enables it to enter, and become "trapped" within the tumor cell. By selectively targeting tumor cells using 2DG-linked compounds, Marillion Pharmaceuticals is building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.

The new company will be led by Dr. Zahed Subhan, an experienced biotech executive who most recently served as CEO of Nuevolution A/S. Marillion Pharmaceuticals will use Greenhouse funds from BioAdvance to validate this new approach to cancer treatment.

Management and Principal Investigators

Zahed Subhan, Ph.D., MBA, LLB., Chief Executive Officer, was most recently CEO of Nuevolution A/S, an emerging Danish drug discovery company. Dr. Subhan has more than 20 years experience in senior research and business positions with Sanofi- Synthelabo, Glaxo Wellcome, Dupont Merck, Gemini Genomics and Locus Pharmaceuticals, and has been responsible for numerous collaborations and successful new product launches. He holds degrees in science, business and law.

Gang Zheng, Ph.D., Scientific Co-Founder, is Assistant Professor in the Department of Radiology at the University of Pennsylvania and a medicinal chemist with research interests in novel imaging and drug delivery technologies. He is the director of the chemistry core of the University of Pennsylvania's Molecular Imaging Center and has authored or co-authored numerous peer-reviewed articles. An inventor on four patent applications, Dr. Zheng received a B.S. degree from Hangzhou University, an M.S. degree from Hampton University and a Ph.D. from the University of Buffalo, followed by postdoctoral work at Roswell Park Cancer Institute.

Jerry Glickson, Ph.D., Scientific Co-Founder, is Director of Molecular Imaging and a Professor in the Departments of Radiology and Biochemistry & Biophysics at the University of Pennsylvania (1996-present). A graduate of Columbia University (B.A., M.A. and Ph.D. in physical chemistry), and a postdoctoral fellow at DuPont Central Research (1968-70), he was a Professor of Radiology and Director of NMR Research at Johns Hopkins University School of Medicine (1984-1996) and Professor of Biochemistry and Director of the Cancer Center NMR Core at the University of Alabama in Birmingham (1970-1984). Dr. Glickson has published over 190 peer-reviewed scientific articles, book chapters and books.

For additional information contact Dr. Zahed Subhan, CEO, Marillion Pharmaceuticals at zsubhan@marillionpharma.com.